/QNCX
QNCX Stock - Quince Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$3.57+2.59%
+$0.09 (+2.59%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.93
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for QNCX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.53 – $3.61
TARGET (TP)$4.11
STOP LOSS$3.28
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.04
52W High$4.55
52W Low$0.72
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-57,285,000 | $-34,620,000 | $-52,015,000 | $-90,318,000 | $-78,893,000 |
| Net Income | $-56,828,000 | $-31,385,000 | $-51,660,000 | $-89,945,000 | $-76,849,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.31 | $-0.84 | $-1.54 | $-3.03 | $-2.63 |
Company Overview
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$10
Average Target
↑ 166.1% Upside
Now
$9
Low
$10
Average
$10
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 5th 2025 | Citizens JMP | Initiation | Mkt Outperform | $9 |
| March 24th 2025 | Oppenheimer | Initiation | Outperform | $10 |
Earnings History & Surprises
QNCXBeat Rate
47%
Last 15 quarters
Avg Surprise
-3.9%
EPS vs Estimate
Beats / Misses
7/8
Last 12 quarters
Latest EPS
$-0.25
Q4 2025
EPS Surprise History
Q1 24
+21.4%
$-0.22vs$-0.28
Q2 24
No data
Q3 24
No data
Q4 24
+13.3%
$-0.13vs$-0.15
Q1 25
-47.4%
$-0.28vs$-0.19
Q2 25
-41.7%
$-0.34vs$-0.24
Q3 25
-21.4%
$-0.34vs$-0.28
Q4 25
-25.0%
$-0.25vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.20 | $-0.25 | -25.0% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.28 | $-0.34 | -21.4% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.24 | $-0.34 | -41.7% | ✗ MISS |
Q1 2025 | Mar 24, 2025 | $-0.19 | $-0.28 | -47.4% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.15 | $-0.13 | +13.3% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | — | $-0.18 | — | — |
Q2 2024 | Apr 1, 2024 | — | $-0.21 | — | — |
Q1 2024 | Feb 14, 2024 | $-0.28 | $-0.22 | +21.4% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | — | $-0.15 | — | — |
Q3 2023 | Aug 3, 2023 | — | $-0.14 | — | — |
Q2 2023 | May 15, 2023 | $-0.31 | $-0.34 | -10.0% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $-0.29 | $-0.13 | +54.8% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.28 | $-0.22 | +21.4% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.74 | $-0.51 | +31.1% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.55 | $-0.72 | -30.9% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-0.65 | $-0.78 | -20.0% | ✗ MISS |
Q4 2021 | Oct 29, 2021 | $-0.74 | $-0.73 | +1.4% | ✓ BEAT |
Q3 2021 | Aug 6, 2021 | $-0.76 | $-0.74 | +2.6% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-0.72 | $-0.78 | -8.3% | ✗ MISS |
Latest News
D. Boral Capital Maintains Buy on Quince Therapeutics, Raises Price Target to $5
📈 PositiveBenzinga•Dec 15, 2025, 07:28 PM
Quince Therapeutics Says Last Patient Completed Last Visit In Pivotal Phase 3 NEAT Clinical Trial Of eDSP, In Patients With Ataxia-Telangiectasia; Expects To Report Topline Results From In Q1 2026
➖ NeutralBenzinga•Dec 15, 2025, 01:07 PM
D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $4 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 02:01 PM
Quince Therapeutics Q3 EPS $(0.25) Misses $(0.21) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 09:38 PM
Quince Therapeutics shares are trading higher after the company said an independent data and safety monitoring board found no safety concerns in its Phase 3 NEAT trial and recommended the study continue without changes.
📈 PositiveBenzinga•Nov 10, 2025, 09:21 PM
Quince Therapeutics Says No Safety Concerns Identified By Independent Data And Safety Monitoring Board In Phase 3 NEAT Clinical Trial, iDSMB Recommended Study Continue Without Modifications
📈 PositiveBenzinga•Nov 10, 2025, 09:19 PM
Quince Therapeutics Announces Poster Presentation Of Patient-Reported Walking Capacity In Children With Ataxia-Telangiectasia At 54th CNS Annual Meeting
➖ NeutralBenzinga•Oct 9, 2025, 08:08 PM
D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $4 Price Target
📈 PositiveBenzinga•Sep 26, 2025, 11:27 AM
Quince Therapeutics Publishes Advanced PK Modeling Study Of Phase 3 Asset eDSP In A-T Patients And Healthy Adults In ASCPT Journal PSP
📈 PositiveBenzinga•Sep 25, 2025, 08:07 PM
Quince Therapeutics announces pricing of up to $22M private placement; shares up 22%
📈 PositiveSeeking Alpha•Jun 12, 2025, 09:31 PM
Frequently Asked Questions about QNCX
What is QNCX's current stock price?
Quince Therapeutics, Inc. (QNCX) is currently trading at $3.57 per share. The stock has moved +2.59% today.
What is the analyst price target for QNCX?
No analyst price targets are currently available for this stock.
What sector is Quince Therapeutics, Inc. in?
Quince Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is QNCX's market cap?
Quince Therapeutics, Inc. has a market capitalization of $0.20 billion, making it a small-cap company.
Does QNCX pay dividends?
No, Quince Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADVM
Adverum Biotechnologies, Inc.
$4.36
Mkt Cap: $0.1B
ALXO
ALX Oncology Holdings Inc.
$1.45
Mkt Cap: $0.1B
ATYR
aTyr Pharma, Inc.
$0.75
Mkt Cap: $0.1B
CAMP
CAMP4 Therapeutics Corporation
$6.38
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
DTIL
Precision BioSciences, Inc.
$4.49
Mkt Cap: $0.1B
GUTS
Fractyl Health, Inc. Common Stock
$2.20
Mkt Cap: $0.2B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
KLRS
Kalaris Therapeutics Inc
$9.13
Mkt Cap: $0.2B
MGX
Metagenomi, Inc. Common Stock
$1.76
Mkt Cap: $0.1B
Explore stocks similar to QNCX for comparison